In Reply
- PMID: 35675622
- DOI: 10.1097/AOG.0000000000004817
In Reply
Conflict of interest statement
Financial Disclosure Brittany Davidson reports receiving funding from GSK. Robert Wenham reports money was paid to his institution (Gynecologic Oncology Group Block Grant). Yovanni Casablanca reports receiving funding from AstraZeneca and owns stock in Regeneron and Pfizer. Nick M. Spirtos reports money was paid to his institution from the NRG/GOG Foundation. They receive per-capita reimbursement that does not cover their costs and have received such monies for the last 30 years. The other authors did not report any potential conflicts of interest.
References
-
- Chan JK, Tian C, Monk BJ, Herzog T, Kapp DS, Bell J, et al. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer 2008;112:220–10. doi: 10.1002/cncr.23390 - DOI
-
- Chan J, Fuh K, Shin J, Cheung M, Powell C, Chen LM, et al. The treatment and outcomes of early-stage epithelial ovarian cancer: have we made any progress? Br J Cancer 2008;98:1191–6. doi: 10.1038/sj.bjc.6604299 - DOI
-
- Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010;363:1532–43. doi: 10.1056/NEJMoa1008433 - DOI
-
- Brown J, Frumovitz M. Mucinous tumors of the ovary: current thoughts on diagnosis and management. Curr Oncol Rep 2014;16:389. doi: 10.1007/s11912-014-0389-x - DOI
-
- Chan JK, Tian C, Kesterson JP, Monk BJ, Kapp DS, Davidson B, et al. Symptoms of women with high-risk early-stage ovarian cancer. Obstet Gynecol 2022;139:157–62. doi: 10.1097/AOG.0000000000004642 - DOI
LinkOut - more resources
Full Text Sources